

NewGen Granted Composition of Matter patent for NT-113

Patent coverage through 2032

MENLO PARK, CA (August 10, 2015) -- NewGen Therapeutics, Inc., a pre-clinical stage biotherapeutic company, today announced the United States Patent and Trademark Office (USPTO) had issued United States Patent No. 9,090,588 entitled "Alkyne substituted quinazoline compounds and methods of use". This patent will expire in 2032, absent any patent term extensions, and covers the composition of matter of NewGen's lead candidate NT-113, a potentially best-in-class irreversible pan-erbB inhibitor with high brain penetrance

NT-113 was designed to penetrate the blood brain barrier to treat erbB (EGFR, HER2 & HER4) altered solid tumors that originate or metastasize to the brain. Approximately 90% of all solid tumors harbor at least one erbB alteration. "With better control of systemic cancers from newer agents, progression is more often occurring in the brain" said Harry D. Pedersen, President and Chief Executive Officer of NewGen Therapeutics. "Existing agents have limited ability to cross the blood brain barrier while NT-113 reaches concentrations up to 8X higher in brain versus plasma in animal studies. NT-113 has the potential to treat EGFR altered non-small cell lung patients who develop brain metastases, EGFR altered glioblastoma patients and HER2 altered breast cancer patients with brain metastases."

"The issuance of this patent further validates our approach to the discovery and development of novel targeted anti-cancer therapeutics," said Harry D. Pedersen, President and Chief Executive officer of NewGen Therapeutics. "

About NewGen

NewGen Therapeutics is a privately held pharmaceutical company developing patient-targeted cancer drugs that are designed to overcome limitations of currently available therapies. The company's pipeline includes multiple programs with novel small molecule drug leads against clinically important targets, each addressed to significant medical needs. NT-113, a potent irreversible pan-erbB inhibitor with high brain penetration, is the company's most advanced program and has demonstrated anti-cancer activity in multiple intracranial patient derived xenograft (PDX) mouse models. NT-113 is planned to enter Phase 1 clinical trials in 2017.

NewGen's strategy is to discover and develop novel targeted anti-cancer agents. and then partner with pharmaceutical companies for clinical development and commercialization. For more information, please visit our website at <http://www.newgenther.com>.



3475 Edison Way, Ste. R, Menlo Park, CA 94025 tel (650) 995-7508

For Further Information Contact:

Harry Pedersen
NewGen Therapeutics
+1.650.995.7508 ext. 101
ir@newgenther.com

For Media Inquiries:

Joan Kureczka
Kureczka/Martin Associates
+1.415.821.2413
Joan@kureczka-martin.com